MarketCap
Facebook
X
Telegram
Aeterna Zentaris Net Income | AEZS
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Aeterna Zentaris
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -10.4 M | -15.3 M | -3.48 M | 3.45 M | -8.37 M | -5.12 M | -6.04 M | 4.19 M | -16.8 M | -25 M | 4.15 M | -16.6 M | 6.82 M | -20.4 M | -27.1 M |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.82 M | -27.1 M | -9.06 M |
Quarterly Net Income Aeterna Zentaris
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -10.4 M | -1.82 M | -2.7 M | -3.66 M | -15.3 M | -5.76 M | -1.42 M | -5.75 M | -3.48 M | -4.14 M | -2.52 M | -4.26 M | - | - | - | -2.64 M | - | -1.7 M | -2.04 M | -1.46 M | - | -1.14 M | -3.45 M | 779 K | - | -331 K | 206 K | -4.91 M | - | -2.51 M | -2.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 779 K | -15.3 M | -3.46 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Rigel Pharmaceuticals
RIGL
|
367 M | $ 49.95 | 3.78 % | $ 898 M |  USA |
 |
Compugen Ltd.
CGEN
|
35.3 M | $ 1.89 | -2.84 % | $ 177 M |  Israel |
 |
Relay Therapeutics
RLAY
|
-276 M | $ 18.16 | -0.11 % | $ 3.12 B | USA |
 |
Coherus BioSciences
CHRS
|
168 M | $ 1.0 | -0.5 % | $ 117 M | USA |
 |
Calithera Biosciences
CALA
|
-39.6 M | - | -10.95 % | $ 876 K | USA |
 |
Royalty Pharma plc
RPRX
|
771 M | $ 64.76 | 1.4 % | $ 27.8 B | USA |
 |
Rhythm Pharmaceuticals
RYTM
|
-197 K | $ 89.56 | 0.32 % | $ 5.82 B | USA |
 |
Rezolute
RZLT
|
-77.6 M | $ 3.82 | -1.04 % | $ 397 M | USA |
|
Applied Molecular Transport
AMTI
|
-126 M | - | - | $ 10.1 M | USA |
 |
Aprea Therapeutics
APRE
|
-12.6 M | $ 0.43 | -16.94 % | $ 2.81 M | USA |
 |
Sana Biotechnology
SANA
|
-244 M | $ 2.36 | 1.29 % | $ 598 M | USA |
 |
Molecular Templates
MTEM
|
-8.12 M | - | -23.43 % | $ 495 K | USA |
 |
PDS Biotechnology Corporation
PDSB
|
-7.56 M | $ 1.07 | -4.05 % | $ 49.6 M | USA |
 |
BioXcel Therapeutics
BTAI
|
-69.9 M | $ 0.07 | 9.81 % | $ 855 K | USA |
 |
Seer
SEER
|
-73.6 M | $ 1.93 | -2.03 % | $ 107 M | USA |
 |
CohBar
CWBR
|
-12.2 M | - | -15.44 % | $ 2.2 M | USA |
 |
SIGA Technologies
SIGA
|
23.3 M | $ 3.16 | 1.12 % | $ 226 M | USA |
 |
NeuBase Therapeutics
NBSE
|
-4.37 M | - | -1.56 % | $ 12.3 M | USA |
 |
Olema Pharmaceuticals
OLMA
|
-162 M | $ 6.61 | 3.04 % | $ 575 M | USA |
 |
Sol-Gel Technologies Ltd.
SLGL
|
-6.13 M | $ 70.54 | 1.57 % | $ 197 M | Israel |
|
Silence Therapeutics plc
SLN
|
-43.3 M | $ 19.77 | 0.48 % | $ 2.8 B |  Britain |
 |
Deciphera Pharmaceuticals
DCPH
|
-195 M | - | - | $ 2.18 B | USA |
 |
Arena Pharmaceuticals
ARNA
|
-616 M | - | -6.81 % | $ 3.04 B | USA |
 |
Scopus BioPharma
SCPS
|
-11.6 M | - | -48.37 % | $ 3.71 M | USA |
 |
Syndax Pharmaceuticals
SNDX
|
-285 M | $ 13.21 | -1.42 % | $ 1.14 B | USA |
 |
Soligenix
SNGX
|
-11.1 M | $ 0.35 | -4.08 % | $ 1.82 M | USA |
 |
scPharmaceuticals
SCPH
|
-85.1 M | - | - | $ 218 M | USA |
 |
Spruce Biosciences
SPRB
|
-39 M | $ 43.74 | -3.12 % | $ 33.5 M | USA |
 |
Spero Therapeutics
SPRO
|
8.57 M | $ 1.07 | -4.05 % | $ 59.9 M | USA |
 |
Entasis Therapeutics Holdings
ETTX
|
-47.1 M | - | - | $ 105 M | USA |
 |
Athersys
ATHX
|
-72.5 M | - | 3.77 % | $ 22.4 M | USA |
 |
Sarepta Therapeutics
SRPT
|
-713 M | $ 17.99 | 0.73 % | $ 1.8 B | USA |
 |
Global Blood Therapeutics
GBT
|
-303 M | - | - | $ 4.62 B | USA |
 |
Sutro Biopharma
STRO
|
-191 M | $ 8.79 | -5.79 % | $ 74.7 M | USA |
 |
Shattuck Labs
STTK
|
-48.8 M | $ 5.55 | 1.09 % | $ 386 M | USA |
 |
Supernus Pharmaceuticals
SUPN
|
-38.6 M | $ 40.79 | 0.22 % | $ 2.3 B | USA |
 |
Savara
SVRA
|
-119 M | $ 4.53 | 7.23 % | $ 1.01 B | USA |
 |
China SXT Pharmaceuticals
SXTC
|
-6.21 M | $ 3.49 | -14.88 % | $ 2.37 M |  China |
 |
Takeda Pharmaceutical Company Limited
TAK
|
108 B | $ 20.45 | 1.01 % | $ 32.3 B |  Japan |
 |
Inozyme Pharma
INZY
|
-102 M | - | - | $ 207 M | USA |
 |
BioCardia
BCDA
|
-8.23 M | $ 0.89 | -3.28 % | $ 5.93 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
-15.9 M | $ 4.53 | -8.85 % | $ 2.01 M | USA |
 |
Cocrystal Pharma
COCP
|
-8.83 M | $ 0.97 | 2.11 % | $ 11 M | USA |
|
Protara Therapeutics
TARA
|
-57.4 M | $ 2.36 | 1.07 % | $ 101 M | USA |
 |
Tarsus Pharmaceuticals
TARS
|
-66 M | $ 69.94 | 2.55 % | $ 2.92 B | USA |
 |
Idera Pharmaceuticals
IDRA
|
-23.4 M | - | -23.04 % | $ 26.6 M | USA |
 |
Teva Pharmaceutical Industries Limited
TEVA
|
1.41 B | $ 40.03 | 1.57 % | $ 45.8 B | Israel |
 |
Collegium Pharmaceutical
COLL
|
63 M | $ 23.21 | 1.09 % | $ 735 M | USA |
 |
NanoString Technologies
NSTG
|
-160 M | - | -37.43 % | $ 5.1 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
99.7 M | $ 87.25 | 1.62 % | $ 9.06 B | USA |